Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results

In patients with extensive-stage tiny compartment lung crab (ES-SCLC), tarlatamab, a bispecific T-cell engager, positive durvalumab arsenic first-line attraction therapy extended median wide endurance by much than 8 months, much than tripled progression-free endurance and reduced the hazard of decease by 58% compared to durvalumab alone, according to results of the signifier 3 open-label, multicenter, randomized DeLLphi-305 study.